| Serial Number | 97977591 |
| Word Mark | ENTOS |
| Filing Date | Wednesday, September 14, 2022 |
| Status | 681 - PUBLICATION/ISSUE REVIEW COMPLETE |
| Status Date | Tuesday, March 26, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, April 30, 2024 |
| Goods and Services | Custom manufacture of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies for others; custom manufacturing of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies |
| Translation of Words in Mark | The English translation of the word "Entos" in the mark is "within". |
| Goods and Services | Medical therapy services, namely, gene therapy services; medical analysis services, namely, RNA or DNA analysis for virus diagnosis and prognosis; medical information services, namely, providing information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies; on-line information services, namely, providing medical information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies; genetic testing for medical purposes |
| Goods and Services | Advisory services relating to gene therapy research; research in the field of gene therapy; research and development of vaccines and medicines; information on the subject of scientific research in the field of biotechnology; genetic testing for scientific research purposes; scientific research in the field of genetics and genetic engineering; research and development in the pharmaceutical and biotechnology fields; pharmaceutical research and development in the field of therapeutic and diagnostic products; scientific research, pharmaceutical research, medical research, technical consultation in the field of pharmaceutical studies and product development for others in the field of biotechnology and product development of pharmaceuticals, therapeutic agents and medical devices; research and product development in the field of human vaccines, recombinant proteins and antibodies for therapeutic use; high-throughput vaccine engineering services; medical and scientific research services of proprietary recombinant protein platform technologies designed to lead to new human vaccines, therapeutic proteins and antibodies; medical and scientific research services relating to infectious diseases; development of new products for others in the field of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies; medical and scientific research regarding clinical trial studies on new vaccine candidates |
| International Class | 040 - Treatment of materials. |
| US Class Codes | 100, 103, 106 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, September 29, 2022 |
| Primary Code | 040 |
| First Use Anywhere Date | Thursday, March 31, 2011 |
| First Use In Commerce Date | Tuesday, January 23, 2018 |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, September 29, 2022 |
| Primary Code | 042 |
| First Use Anywhere Date | Thursday, March 31, 2011 |
| First Use In Commerce Date | Thursday, March 31, 2011 |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, September 29, 2022 |
| Primary Code | 044 |
| First Use Anywhere Date | Thursday, March 31, 2011 |
| First Use In Commerce Date | Thursday, March 31, 2011 |
| Party Name | Entos Pharmaceuticals Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Edmonton, Alberta T5J4P6 CA |
| Event Date | Event Description |
| Wednesday, April 10, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Friday, March 22, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Tuesday, March 12, 2024 | EXAMINER'S AMENDMENT ENTERED |
| Monday, March 11, 2024 | ASSIGNED TO LIE |
| Monday, March 11, 2024 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Monday, March 11, 2024 | EXAMINERS AMENDMENT E-MAILED |
| Monday, March 11, 2024 | EXAMINERS AMENDMENT -WRITTEN |
| Friday, March 8, 2024 | DIVISIONAL PROCESSING COMPLETE |
| Thursday, November 16, 2023 | DIVISIONAL REQUEST RECEIVED |
| Wednesday, March 6, 2024 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Thursday, November 16, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, November 16, 2023 | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED |
| Thursday, November 16, 2023 | TEAS VOLUNTARY AMENDMENT RECEIVED |
| Thursday, November 16, 2023 | TEAS REQUEST TO DIVIDE RECEIVED |
| Wednesday, September 27, 2023 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| Wednesday, September 27, 2023 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| Tuesday, June 27, 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Tuesday, June 27, 2023 | NON-FINAL ACTION E-MAILED |
| Tuesday, June 27, 2023 | NON-FINAL ACTION WRITTEN |
| Monday, June 26, 2023 | ASSIGNED TO EXAMINER |
| Thursday, September 29, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Saturday, September 17, 2022 | NEW APPLICATION ENTERED |